178 related articles for article (PubMed ID: 24942375)
21. Randomized, open-label, tolterodine-controlled, comparative study of the novel antimuscarinic agent imidafenacin in patients with overactive bladder.
Pushkar DY; Kasyan GR; Kolontarev KB; Sharvadze GG; Mukhametshina EI
Neurourol Urodyn; 2019 Jun; 38(5):1313-1321. PubMed ID: 30888691
[TBL] [Abstract][Full Text] [Related]
22. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
23. Psychometric assessment of female overactive bladder syndrome and antimuscarinics-related effects.
Hsiao SM; Liao SC; Chen CH; Chang TC; Lin HH
Maturitas; 2014 Dec; 79(4):428-34. PubMed ID: 25238744
[TBL] [Abstract][Full Text] [Related]
24. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
[TBL] [Abstract][Full Text] [Related]
25. Psychometric properties of the incontinence utility index among patients with idiopathic overactive bladder: data from two multicenter, double-blind, randomized, Phase 3, placebo-controlled clinical trials.
Castejón N; Khalaf K; Ni Q; Cuervo J; Patrick DL
Health Qual Life Outcomes; 2015 Aug; 13():116. PubMed ID: 26231052
[TBL] [Abstract][Full Text] [Related]
26. Psychometric performance of the incontinence quality-of-life questionnaire among patients with overactive bladder and urinary incontinence.
Patrick DL; Khalaf KM; Dmochowski R; Kowalski JW; Globe DR
Clin Ther; 2013 Jun; 35(6):836-45. PubMed ID: 23747076
[TBL] [Abstract][Full Text] [Related]
27. Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Serels SR; Toglia MR; Forero-Schwanhaeuser S; He W
Curr Med Res Opin; 2010 Oct; 26(10):2277-85. PubMed ID: 20707767
[TBL] [Abstract][Full Text] [Related]
28. The validation of the Dutch OAB-q SF: An overactive bladder symptom bother and health-related quality of life short-form questionnaire.
Groenendijk IM; Scheepe JR; Noordhoff TC; Blok BFM
Neurourol Urodyn; 2019 Aug; 38(6):1775-1782. PubMed ID: 31215693
[TBL] [Abstract][Full Text] [Related]
29. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
30. Establishing the content validity of the King's Health Questionnaire in men and women with overactive bladder in the US.
Margolis MK; Vats V; Coyne KS; Kelleher C
Patient; 2011; 4(3):177-87. PubMed ID: 21766913
[TBL] [Abstract][Full Text] [Related]
31. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported outcomes with the β
Khullar V; Amarenco G; Angulo JC; Blauwet MB; Nazir J; Odeyemi IA; Hakimi Z
Neurourol Urodyn; 2016 Nov; 35(8):987-994. PubMed ID: 26288118
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of fesoterodine 8 mg in subjects with overactive bladder after a suboptimal response to tolterodine ER.
Kaplan SA; Cardozo L; Herschorn S; Grenabo L; Carlsson M; Arumi D; Crook TJ; Whelan L; Scholfield D; Ntanios F;
Int J Clin Pract; 2014 Sep; 68(9):1065-73. PubMed ID: 24898471
[TBL] [Abstract][Full Text] [Related]
34. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
[TBL] [Abstract][Full Text] [Related]
35. Correlation between psychological stress levels and the severity of overactive bladder symptoms.
Lai H; Gardner V; Vetter J; Andriole GL
BMC Urol; 2015 Mar; 15():14. PubMed ID: 25887525
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
38. Reproducibility study of Overactive Bladder Symptom Score questionnaire and its response to treatment (RESORT) in Korean population with overactive bladder symptoms.
Jeong SJ; Homma Y; Oh SJ
Qual Life Res; 2014 Feb; 23(1):285-92. PubMed ID: 23715806
[TBL] [Abstract][Full Text] [Related]
39. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
40. Continued symptom improvement in sexually active women with overactive bladder and urgency urinary incontinence treated with tolterodine ER for 6 months.
Rogers RG; Omotosho T; Bachmann G; Sun F; Morrow JD
Int Urogynecol J Pelvic Floor Dysfunct; 2009 Apr; 20(4):381-5. PubMed ID: 19132285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
